Arvinas Inc. (ARVN) is a clinical-stage biopharmaceutical company that develops new drugs to treat cancers and other diseases using its proprietary Protein Targeting Technology platform. This platform enables the company to develop small molecule drugs that selectively destroy cancer cells by targeting specific proteins within them, while leaving normal cells unharmed. The company's lead product candidate, ARV-471, is an estrogen receptor-targeting protein degrader being developed for the treatment of metastatic breast cancer. The company is also developing a pipeline of other product candidates, including ARV-110, which targets the androgen receptor for the treatment of metastatic castration-resistant prostate cancer, and ARV-1502, which targets the estrogen receptor for the treatment of triple-negative breast cancer. Arvinas is headquartered in New Haven, Connecticut and was founded in 2013.
Arvinas Inc. (ARVN) is a clinical-stage biopharmaceutical company that develops new drugs to treat cancers and other diseases using its proprietary Protein Targeting Technology platform. This platform enables the company to develop small molecule drugs that selectively destroy cancer cells by targeting specific proteins within them, while leaving normal cells unharmed. The company's lead product candidate, ARV-471, is an estrogen receptor-targeting protein degrader being developed for the treatment of metastatic breast cancer. The company is also developing a pipeline of other product candidates, including ARV-110, which targets the androgen receptor for the treatment of metastatic castration-resistant prostate cancer, and ARV-1502, which targets the estrogen receptor for the treatment of triple-negative breast cancer. Arvinas is headquartered in New Haven, Connecticut and was founded in 2013.